DM
FHTX icon

Deerfield Management’s Foghorn Therapeutics FHTX Stock Holding History

Deerfield Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.4M Hold
4,394,367
– – 0.22% 58
2026
Q1 		$21M Buy
4,394,367
+745,156
+20% +$4.09M 0.25% 61
2025
Q4 		$19.7M Buy
3,649,211
+393,697
+12% +$1.78M 0.25% 59
2025
Q3 		$15.9M Hold
3,255,514
– – 0.24% 63
2025
Q2 		$15.3M Hold
3,255,514
– – 0.28% 59
2025
Q1 		$11.9M Hold
3,255,514
– – 0.23% 65
2024
Q4 		$15.4M Buy
3,255,514
+227,628
+8% +$1.66M 0.29% 56
2024
Q3 		$28.2M Buy
3,027,886
+509,386
+20% +$3.69M 0.42% 47
2024
Q2 		$14.5M Buy
+2,518,500
New +$15M 0.24% 57
2023
Q4 		– Sell
-777,525
Closed -$3.89M – 228
2023
Q3 		$3.89M Hold
777,525
– – 0.09% 69
2023
Q2 		$5.47M Hold
777,525
– – 0.12% 78
2023
Q1 		$4.82M Hold
777,525
– – 0.11% 82
2022
Q4 		$4.96M Hold
777,525
– – 0.1% 77
2022
Q3 		$6.67M Hold
777,525
– – 0.13% 93
2022
Q2 		$10.6M Buy
777,525
+538,660
+226% +$6.95M 0.22% 77
2022
Q1 		$3.64M Buy
+238,865
New +$3.28M 0.08% 92

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management's FHTX Position: Q2 2026 in Review

Deerfield Management held its Foghorn Therapeutics (FHTX) position steady in Q2 2026 at 4,394,367 shares worth $21.4M. The position accounts for 0.22% of the portfolio, ranked #58.

Deerfield Management first reported a position in FHTX in Q1 2022 and has held it in 16 quarters since. The position peaked at $28.2M in Q3 2024. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Deerfield Management held 4,394,367 shares of Foghorn Therapeutics worth $21.4M as of Q2 2026.
  • Deerfield Management left its Foghorn Therapeutics share count unchanged in Q2 2026.
  • Foghorn Therapeutics made up 0.22% of Deerfield Management's portfolio in Q2 2026, its #58 holding.
  • Deerfield Management first reported a position in Foghorn Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • Deerfield Management's Foghorn Therapeutics position peaked at $28.2M in Q3 2024.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.